Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism.

Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism.
复制标题

DOI:
10.1016/j.molmet.2013.10.002
复制
发表时间:
2014-02
影响因子:
8.1
通讯作者:
Chua S Jr
Chua S Jr
中科院分区:
医学1区
文献类型:
--
作者:
Marcelin G;Jo YH;Li X;Schwartz GJ;Zhang Y;Dun NJ;Lyu RM;Blouet C;Chang JK;Chua S Jr

文献摘要

参考文献

被引文献

相似文献

严格控制血糖波动一直是 2 型糖尿病患者的长期治疗目标,以改善与高血糖相关的发病率和死亡率。成纤维细胞生长因子 (FGF) 19 是一种餐后释放的类激素肠因子,可作为代谢性疾病(包括糖尿病和肥胖症)的潜在治疗剂。值得注意的是,FGF19 治疗具有降血糖作用,在遗传性和获得性胰岛素抵抗模型中仍然有效。在这里,我们提供了中枢神经系统对外周施用的 FGF19 做出反应的证据。然后,在两种胰岛素抵抗、瘦素缺乏和高脂肪饮食喂养的小鼠模型中,第三次脑室内注射 FGF19 改善了血糖状态,降低了胰岛素抵抗并增强了外周胰岛素信号传导。此外,我们的研究强调了中枢 FGF19 作用的新机制,涉及抑制 AGRP/NPY 神经元活动。总体而言,我们的工作揭示了 FGF19 诱导的新调控途径,这将有助于设计控制肥胖糖尿病的新策略。
Tight control of glucose excursions has been a long-standing goal of treatment for patients with type 2 diabetes mellitus in order to ameliorate the morbidity and mortality associated with hyperglycemia. Fibroblast growth factor (FGF) 19 is a hormone-like enterokine released postprandially that emerged as a potential therapeutic agent for metabolic disorders, including diabetes and obesity. Remarkably, FGF19 treatment has hypoglycemic actions that remain potent in models of genetic and acquired insulin resistance. Here, we provided evidence that the central nervous system responds to FGF19 administered in the periphery. Then, in two mouse models of insulin resistance, leptin-deficiency and high-fat diet feeding, third intra-cerebro-ventricular infusions of FGF19 improved glycemic status, reduced insulin resistance and potentiated insulin signaling in the periphery. In addition, our study highlights a new mechanism of central FGF19 action, involving the suppression of AGRP/NPY neuronal activity. Overall, our work unveils novel regulatory pathways induced by FGF19 that will be useful in the design of novel strategies to control diabetes in obesity.
DOI: 10.1002/jcp.21357
发表时间: 2008-04-01
影响因子: 5.6
作者:
Kharitonenkov, Alexei;Dunbar, James D.;Shanafelt, Armen B.
通讯作者: Shanafelt, Armen B.
DOI: 10.1371/journal.pone.0033603
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Ge H;Baribault H;Vonderfecht S;Lemon B;Weiszmann J;Gardner J;Lee KJ;Gupte J;Mookherjee P;Wang M;Sheng J;Wu X;Li Y
通讯作者: Li Y
DOI: 10.1016/j.neulet.2010.10.019
发表时间: 2011-01-07
影响因子: 2.5
作者:
Ciofi, Philippe
通讯作者: Ciofi, Philippe
DOI: 10.1038/nrd2792
发表时间: 2009-03
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
通讯作者: --
DOI: 10.1210/en.2011-2145
发表时间: 2012-08-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Pournaras, Dimitri J.;Glicksman, Clare;le Roux, Carel W.
通讯作者: le Roux, Carel W.